- Home
- OFS vs ALGS Comparison
OFS vs ALGS Comparison
Compare OFS & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OFS | ALGS |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | United States | United States |
| Employees | 47 | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.2M | 37.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | OFS | ALGS |
|---|---|---|
| Price | $3.92 | $6.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | 57.6K | ★ 207.9K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 16.83% | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | N/A | $32.20 |
| Revenue Next Year | N/A | $4.71 |
| P/E Ratio | $17.44 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.72 | $4.47 |
| 52 Week High | $9.31 | $13.69 |
Technical Indicators
Market Signals| Indicator | OFS | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 52.10 | 39.94 |
| Support Level | $3.57 | N/A |
| Resistance Level | $4.08 | $8.30 |
| Average True Range (ATR) | 0.20 | 0.47 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 49.56 | 15.00 |
Price Performance
Historical ComparisonAbout OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to provide its stockholders with both current income and capital appreciation through debt investments and, to a lesser extent, equity investments.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.